Craft
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
banner
UBI Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.

Stock Price

NT$13.9

2024-05-06

Market Capitalization

NT$1.7 B

2024-05-06

Revenue

NT$538.8 M

FY, 2024

CreditSafe Score

?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn more

Financial Statements

TWDFY, 2018FY, 2019FY, 2020FY, 2021FY, 2022FY, 2023FY, 2024
Revenue423.9M479.6M477.6M644.3M633.8M648.6M538.8M
Cost of goods sold305.3M296.4M258.6M215.7M194.4M281.0M137.2M
Gross profit137.8M211.4M236.9M432.0M442.8M370.1M407.7M
Gross profit margin, %32.5%44.1%49.6%67.0%69.9%57.1%75.7%
Operating expense total340.1M346.0M279.2M228.1M242.9M189.1M219.0M
Depreciation and amortization35.3M109.7M114.7M159.2M158.8M170.6M396.6M
EBITDA(202.3M)(134.6M)(42.3M)203.8M199.9M181.0M188.7M
EBITDA margin, %-47.7%-28.1%-8.9%31.6%31.5%27.9%35.0%
EBIT(237.7M)(244.5M)(158.1M)44.4M41.1M10.1M(179.4M)
EBIT margin, %-56.1%-51.0%-33.1%6.9%6.5%1.6%-33.3%
Interest income974.0K15.6M2.3M181.0K1.4M4.9M5.2M
Interest expense13.1M25.9M20.0M18.4M11.7M10.8M12.1M
Pre tax profit(249.5M)(255.4M)(90.3M)23.8M54.3M2.6M(175.6M)
Income tax expense1.4M1.4M7.1M1.8M(1.1M)
Net Income(249.5M)(255.4M)(91.6M)22.4M47.2M803.0K(174.5M)

Footer menu